Can Quantitative MRI After cTACE Help Predict Survival ?
| Status: | Completed |
|---|---|
| Conditions: | Liver Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 89 |
| Updated: | 9/29/2018 |
| Start Date: | August 2014 |
| End Date: | March 7, 2018 |
Can Quantitative MRI After Conventional Transarterial Chemoembolization (cTACE) Help Predict Survival ?
Transcatheter arterial chemoembolization (TACE) is a widely accepted palliative therapy for
the treatment of HCC. Palliative means that it does not cure the disease prolongs your life
and improves quality of life. During TACE, a mixture of chemotherapy drugs is combined with
an oil called lipiodol. Lipiodol has a role as both drug carrier and embolic agent (a
material that blocks blood flow to tumors). The lipiodol/chemotherapy mixture is injected
into an artery (blood vessel) directly supplying blood to a HCC tumor.
Lipiodol is made up of fat and water which can be seen on MRI. Therefore, MRI can be used to
quantify the amount of lipiodol delivered to the HCC tumors.
In this study, the investigators want to see if patient survival is related to the amount of
lipiodol delivered to HCC tumors.
the treatment of HCC. Palliative means that it does not cure the disease prolongs your life
and improves quality of life. During TACE, a mixture of chemotherapy drugs is combined with
an oil called lipiodol. Lipiodol has a role as both drug carrier and embolic agent (a
material that blocks blood flow to tumors). The lipiodol/chemotherapy mixture is injected
into an artery (blood vessel) directly supplying blood to a HCC tumor.
Lipiodol is made up of fat and water which can be seen on MRI. Therefore, MRI can be used to
quantify the amount of lipiodol delivered to the HCC tumors.
In this study, the investigators want to see if patient survival is related to the amount of
lipiodol delivered to HCC tumors.
Inclusion Criteria:
- Prospective studies will be performed in 20 patients with Hepatocellular Carcinoma
(HCC) independently scheduled to undergo TACE; tumors in each of these candidates will
already have been deemed un-resectable.
- Reasons may include
- concurrent co-morbidities including cardiac or respiratory compromise
- recurrent or multi-lobar disease
- cirrhosis or portal hypertension
- vascular invasion
- high tumor burden
- contraindications to general anesthesia.
- Diagnosis of HCC will have been established by a) biopsy or b) non-invasively, based
upon > 2cm diameter tumor with characteristic imaging findings in the setting of
cirrhosis.
- Male or female aged 18 to 89 years, all ethnicities
Exclusion Criteria:
- Infiltrative or diffuse HCC.
- Does not meet inclusion criteria.
- Pregnant women.
- Individuals with pacemakers or other non-MRI compatible metallic implants.
- Hemodialysis patients or patients with severely impaired renal function.
- Individuals with severe claustrophobia or unwilling to get a MRI.
We found this trial at
1
site
Click here to add this to my saved trials
